Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Number of items: 6.

Holland-Hart, Daniella ORCID: https://orcid.org/0000-0002-1127-5152, Carucci, Margherita, Slusarczyk, Magdalena ORCID: https://orcid.org/0000-0002-4707-7190, Longo, Mirella ORCID: https://orcid.org/0000-0002-9867-3806, Campbell, Susan, Irving, Alys, Noble, Simon ORCID: https://orcid.org/0000-0001-5425-2383, Jayson, Gordon and Hopewell-Kelly, Noreen 2025. Participants’ perspectives of the advanced ovarian cancer biomarker study VALTIVE1: a qualitative study. BMJ Open 15 (7) , e088474. 10.1136/bmjopen-2024-088474
file

Carucci, Margherita, Clamp, Andrew, Zhou, Cong, Hurt, Chris, Glasspool, Rosalind, Monaghan, Phillip J., Thirkettle, Sally, Wheatley, Michael, Mahmood, Madia, Narasimham, Monica, Cox, Tracy, Morrison, Hilary, Campbell, Susan, Nelson, Annmarie, Holland-Hart, Daniella ORCID: https://orcid.org/0000-0002-1127-5152, Hopewell-Kelly, Noreen, Thomas, Abin, Porter, Catharine, Slusarczyk, Magdalena ORCID: https://orcid.org/0000-0002-4707-7190, Irving, Alys, Dive, Caroline, Adams, Richard and Jayson, Gordon C. 2024. The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors. BMC Cancer 24 (1) , 1309. 10.1186/s12885-024-13073-0
file

Beresford, Mark, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Hudson, Zoe, Carucci, Margherita, Ingarfield, Kate, Gee, Julia ORCID: https://orcid.org/0000-0001-6483-2015, Smith, Joanna ORCID: https://orcid.org/0000-0003-4234-6686, Kitson, Terri ORCID: https://orcid.org/0000-0001-6333-046X, Alchami, Fouad, Madden, Tracie-Ann ORCID: https://orcid.org/0000-0001-7880-7873, Hayward, Larrie, Hwang, David, Spensley, Saiqa, Waters, Simon, Wheatley, Duncan and Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1 (1) , 13. 10.1038/s44276-023-00016-8
filefile

Jayson, G., Carucci, Margherita, Hurt, Christopher ORCID: https://orcid.org/0000-0003-1206-8355, Zhou, Cong, Monaghan, Phillip, Wych, Julie, Irving, Alys, Narasimham, Monica, Morrison, Hilary, Campbell, Sue, Glasspool, Rosalind, Longo, Mirella ORCID: https://orcid.org/0000-0002-9867-3806, Nelson, Annmarie ORCID: https://orcid.org/0000-0002-6075-8425, Dive, Caroline, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243 and Clamp, Andrew 2021. VALTIVE1: Validation of Tie2 as a response biomarker for VEGF inhibitors In Ovarian Cancer. Presented at: NCRI Cancer Conference, 2021.

Jones, Robert H. ORCID: https://orcid.org/0000-0003-3576-9496, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Carucci, Margherita, Cox, Catrin, Butler, Rachel, Alchami, Fouad, Madden, Tracie-Ann ORCID: https://orcid.org/0000-0001-7880-7873, Bale, Catherine, Bezecny, Pavel, Joffe, Johnathan, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, Foxley, Andrew and Howell, Sacha J. 2020. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology 21 (3) , pp. 345-347. 10.1016/S1470-2045(19)30817-4
file

Hurt, Christopher N. ORCID: https://orcid.org/0000-0003-1206-8355, Jones, Sadie E. F., Madden, Tracie-Ann ORCID: https://orcid.org/0000-0001-7880-7873, Fiander, Alison, Nordin, Andrew J., Naik, Raj, Powell, Ned, Carucci, Margherita and Tristram, Amanda 2018. Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multi-centre, randomised, phase II trial (RT3VIN). BJOG: An International Journal of Obstetrics and Gynaecology 125 (9) , pp. 1171-1177. 10.1111/1471-0528.15124
file

This list was generated on Sun Jul 27 06:09:49 2025 BST.